MGX
Metagenomi Therapeutics, Inc.
Next earnings Aug 10, 2026 · consensus $-0.57 EPS, $3.87M rev
Last earnings -7.1% on 2026-05-11
$1.25
▲ +5.04%$1.25▼ -14.38%
over 1Y
L $1.14EODHDH $3.33
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+5.0%
1W+5.0%
1M-7.4%
3M-5.3%
YTD-25.1%
1Y-14.4%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 9 analysts
Buy
Conservative balance sheet (liabilities/equity 0.39x); but revenue fell -51.8% YoY.
Revenue (FY2025) $25.2M · FY2025
Metagenomi Therapeutics, Inc. shows $25.2M in FY2025 revenue (-51.8% YoY), a -348.5% net margin, and -55.4% ROE.
Financials · annual, by fiscal year
| Line item | FY23 | FY24 | FY25 |
|---|---|---|---|
| Revenue | $44.8M | $52.3M | $25.2M |
| Gross profit | — | — | — |
| Operating income | -$78.5M | -$88.9M | -$96.0M |
| Net income | -$68.3M | -$78.1M | -$87.9M |
| Diluted EPS | -$20.05 | -$2.36 | -$2.36 |
| Net margin | -152.5% | -149.3% | -348.5% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$5.30M
EV / EBITDA—
EV / Sales0.2
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-186.9%
FCF yield-190.2%
Quality & risk
ROIC (est.)-47.8%
Free cash flow-$89.5M
Total debt—
Net cash$41.7M
Altman Z-Score-2.06 distress
Piotroski F-Score1/7
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+0.6%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗4Period ending 2026-06-092026-06-11open ↗4Period ending 2026-06-092026-06-11open ↗4Period ending 2026-06-092026-06-11open ↗4Period ending 2026-06-092026-06-11open ↗4Period ending 2026-06-052026-06-10open ↗4Period ending 2026-06-052026-06-10open ↗4Period ending 2026-06-052026-06-10open ↗8-KPeriod ending 2026-06-092026-06-10open ↗10-QPeriod ending 2026-03-312026-05-11open ↗8-KPeriod ending 2026-05-112026-05-11open ↗ARSPeriod ending 2025-12-312026-04-27open ↗DEFA14AFiling2026-04-27open ↗
Frequently asked
- Is Metagenomi Therapeutics, Inc. (MGX) a buy?
- MGX currently carries a Avoid rating with 4/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.39x); but revenue fell -51.8% YoY.
- What is Metagenomi Therapeutics, Inc.'s quality score?
- MGX scores 45.03921568627451/100 (grade D) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001785279, latest 10-Q filed 2026-05-11) · EODHD · as of 6/22/2026, 9:52:53 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.